Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SSGJ-707 · 3 trials · 3 indications
Progression-free survival (PFS) is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the blinded IRRC or death due to any cause (whichever occurs first).
Objective response rate
Safety and tolerability assessed by incidence and severity of adverse events
| Arm | Type | Description |
|---|---|---|
| SSGJ-707 | EXPERIMENTAL | Subjects receive SSGJ-707 monotherapy intravenously (IV), selected dose. |
| Pembrolizumab | ACTIVE_COMPARATOR | Subjects receive Pembrolizumab monotherapy intravenously (IV), 200mg q3w. |
| SSGJ-707(dose 1)+ carboplatin + paclitaxel | EXPERIMENTAL | - |
| SSGJ-707(dose 2)+ carboplatin + paclitaxel | EXPERIMENTAL | - |
| SSGJ-707(dose 3)+ carboplatin + paclitaxel | EXPERIMENTAL | - |
| SSGJ-707(dose 4)+ paclitaxel | EXPERIMENTAL | - |
| SSGJ-707(dose 1)+ XELOX | EXPERIMENTAL | - |
| SSGJ-707(dose 1)+ mFOLFOX6 | EXPERIMENTAL | - |
| SSGJ-707(dose 2)+ XELOX | EXPERIMENTAL | - |
| SSGJ-707(dose 2)+ mFOLFOX6 | EXPERIMENTAL | - |
| SSGJ-707+XELOX/mFOLFOX6 | EXPERIMENTAL | - |
| Bevacizumab+XELOX/mFOLFOX6 | ACTIVE_COMPARATOR | - |
| SSGJ-707 monotherapy | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SSGJ-707 | DRUG | Subjects receive SSGJ-707 intravenously. |
| Pembrolizumab | DRUG | Subjects receive Pembrolizumab intravenously. |
| carboplatin | DRUG | chemotherapy |
| paclitaxel | DRUG | chemotherapy |
| Bevacizumab | DRUG | VEGF antibody |
| Oxaliplatin | DRUG | chemotherapy |
| Capecitabine | DRUG | chemotherapy |
| Calcium Folinate | DRUG | chemotherapy |
| 5-fluorouracil | DRUG | chemotherapy |
Inclusion Criteria: 1. Willing to participate in the study voluntarily, agree to comply with and complete all study procedures, and sign the Informed Consent Form (ICF). 2. At least 18 years of age at the time of signing the ICF, regardless of gender. 3. Eastern Cooperative Oncology Group (ECOG) Pe...
Top 20 of 84 competitors
SSGJ-707 is an investigational small molecule being studied for advanced non-small cell lung cancer, advanced or recurrent endometrial cancer, platinum-resistant ovarian cancer, and metastatic colorectal cancer. It is currently in clinical development and has not been approved by regulatory authorities.
SSGJ-707 is being developed by Sunshine Biopharma Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SBFM. The company is conducting clinical trials of SSGJ-707 in China across multiple oncology indications.
SSGJ-707 is in Phase 3 clinical development for advanced non-small cell lung cancer, with a Phase 3 trial currently recruiting participants. It is also being studied in Phase 2 trials for metastatic colorectal cancer and advanced gynecologic cancers. SSGJ-707 remains investigational and is not FDA approved.
SSGJ-707 is being evaluated in three active clinical trials in China. NCT06980272 is a Phase 3 study in advanced non-small cell lung cancer with 420 participants. NCT06493760 is a Phase 2 study in metastatic colorectal cancer with 130 participants. NCT06522828 is a Phase 2 study in advanced gynecologic cancers with 80 participants.
Yes, SSGJ-707 is being studied in a randomized, double-blind, active-controlled trial for advanced non-small cell lung cancer. This Phase 3 study uses an active comparator and is biomarker-selected, enrolling 420 participants aged 18 years and older in China.